St. Jude Optimistic About Symmetry Despite Slower-Than-Expected Adoption
This article was originally published in The Gray Sheet
Executive Summary
Demand for St. Jude Medical's Symmetry anastomotic bypass graft system will continue to grow slowly for the foreseeable future, even though the device is associated with a better overall patency rate than traditional sutures, the company predicts
You may also be interested in...
SynCardia To Bring TAH Ventricular Replacement Before FDA Panel In March
SynCardia's CardioWest Total Artificial Heart (TAH) will be reviewed by FDA's Circulatory System Devices panel March 17 in Gaithersburg, Md
SynCardia To Bring TAH Ventricular Replacement Before FDA Panel In March
SynCardia's CardioWest Total Artificial Heart (TAH) will be reviewed by FDA's Circulatory System Devices panel March 17 in Gaithersburg, Md
SJM Epic Porcine Valve Trial Signals Turnaround Of St. Jude’s Valve Business
St. Jude expects the introduction of its BioCor stented porcine tissue valve in the U.S. later this year to lead a roughly 13% turnaround of the firm's replacement heart valve business in 2003